

## Transforming Gynecologic Health

Aspira Women's Health is dedicated to the discovery, development and distribution of novel bio-analytical solutions that help physicians diagnose gynecologic disease and improve health outcomes for women. Our blood tests use advanced, proprietary algorithms based on nearly two decades of research and clinical experience.

OvaSuite<sup>SM</sup> is the company's commercially-available portfolio of multi-marker ovarian cancer blood tests to assist healthcare providers in making informed treatment decisions for the 1.2 to 1.5 million American women diagnosed with adnexal masses each year. The domestic market opportunity for OvaSuite is estimated at \$600M to \$715M.

EndoCheck<sup>TM</sup> is an in-development blood test to aid in the identification of endometriosis, a debilitating gynecologic disease estimated to impact 6 million American women. This first-of-its kind test is expected to be available by the end of 2023.

## Investment Highlights

- Revenue-generating company with a portfolio of proprietary risk assessment assays targeting ovarian cancer, collectively called OvaSuite
- Experienced management team with proven track record of success
- Broad managed care coverage (Ova1Plus<sup>®</sup> Medicare reimbursement - \$897)
- Strong IP and technology protection
- Transformative pipeline opportunities including a planned 2023 launch of EndoCheck and expansion of OvaWatch<sup>SM</sup> for longitudinal monitoring

## Our OvaSuite Products



OvaWatch, a lab-developed test performed on an FDA approved platform with a 99% Negative Predictive Value, assists in the initial clinical assessment of ovarian malignancy risk in patients with adnexal masses not planned for surgical intervention.



Ova1Plus combines FDA-cleared blood tests, Ova1<sup>®</sup>, and Overa<sup>®</sup>, to assess risk of ovarian malignancy in women with adnexal masses planned for surgery.

## Recent Developments

### 31 Aug 2023

Aspira Women's Health Signed Exclusive Sample Procurement Agreement with The University of Oxford

### 28 Aug 2023

Aspira Women's Health Named Michelle Snider as Senior Vice President, Commercial Strategy and Operations

### 14 Aug 2023

Aspira Women's Health Inc. Reports 23% Revenue Growth and 40%+ Reduction in Cash Used in Operations For the Second Quarter

### 20 July 2023

Aspira Women's Health Inc. Announced \$4.7 mm Registered Direct Common Stock Offering

### 28 June 2023

Aspira Women's Health, Inc. Receives \$1 mm Loan Forgiveness and 6-month Payment Deferral from the Connecticut DECD

## Fast Facts

<b>Ticker (Exchange)</b>	AWH (NASDAQ)
<b>Stock Price</b> (as of 6/30/23)	\$3.31
<b>Market Cap</b> (as of 6/30/23)	\$28.0M
<b>Outstanding Shares</b> (as of 6/30/23)	8.5M
<b>52-Week Range</b>	\$2.78-\$16.05
<b>Avg. Daily Volume</b>	23,497
<b>Headquarters</b>	Austin, TX
<b>Fiscal Year End</b>	December 31
<b>Cash* Available</b> (as of 6/30/23)	\$4.5M
<b>2Q23 Revenues</b> In Millions	\$2.5
YoY Growth	23%

\*incl cash, cash equivalents and restricted cash

## Equity Coverage Analysts

<b>William Blair</b> Andrew Brackmann, CFA	<b>Alliance Global Partners</b> Ben Haynor, CFA
<b>Water Tower Research</b> Sally Yanchus	<b>Cantor Fitzgerald</b> Ross Osborn, CFA

## Executive Officers

**Nicole Sandford**  
CEO, President & Board Member

**Dr. Torsten Hombeck**  
Chief Financial Officer

**Dr. Ryan Phan**  
Chief Scientific and Chief Operating Officer

**Minh Hoang Merchant**  
General Counsel, CCO & Corporate Secretary

## Contact

**Aspira Women's Health, Inc.**  
**Corporate Headquarters**

35 Nutmeg Dr.  
Trumbull CT, 06611  
Phone: (844) 277-4721  
[www.aspirawh.com](http://www.aspirawh.com)